Organoid, Mouse Model, and Biomarker

类器官、小鼠模型和生物标志物

基本信息

批准号：
10684211
负责人：
ALAN D. D'ANDREA
金额：
$ 19.68万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-08-03 至 2025-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10684211
关键词：
Apoptosis Architecture Biological Assay Biological Markers Biological Models Biopsy Cancer Center Cancer cell line Cell Culture Techniques Cell Line Cells Clinical Clinical Trials Collection DNA Repair Development Drug Combinations Drug Evaluation Drug resistance Environment Generations Genes Goals Grant Guidelines Gynecologic Oncology Group ITGB2 gene In Vitro Infrastructure Investigation Laboratories Maintenance Malignant Neoplasms Malignant neoplasm of ovary Modeling Mus Mutation Newly Diagnosed Disease Organoids Ovarian Paracentesis Participant Patients Platinum Poly(ADP-ribose) Polymerase Inhibitor Primary Cell Cultures Protocols documentation Publications Recurrent disease Reproducibility Research Research Personnel Residual Neoplasm Resistance Resistance development Sampling Serous Services Therapeutic procedure Thoracentesis Tissue Banks Validation Work Xenograft Model cancer therapy chemotherapy design drug sensitivity drug testing functional loss functional status in vivo infrastructure development inhibitor insight mouse model neoplastic cell novel strategies patient derived xenograft model programs repository response restoration sample collection therapeutic target therapy resistant treatment response tumor tumorigenic

项目摘要

PROJECT SUMMARY - Core 3: Organoid, Model Systems, and Biomarkers Core The overall purpose of the Organoids, Model Systems, and Biomarkers Core of this Dana- Farber/Harvard Cancer Center Ovarian Cancer SPORE application is to provide core services to the three projects and to the other cores. The core will be directed by Drs. Alan D’Andrea, Joyce Liu, and Neil Horowitz. A primary feature of the core is our recent advances in the generation of short-term ovarian cancer organoid cultures which closely mimic the tumor from which they are derived (Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, Yang C, Morizane R, Kochupurakkal B, Do KT, Konstantinopoulos PA, Liu JF, Bonventre JV, Matulonis UA, Shapiro GI, Berkowitz RS, Crum CP, D’Andrea AD. Prediction of DNA Repair Inhibitor Response in Short Term Patient-derived Ovarian Cancer Organoids. Cancer Discov. 2018 Sep 13. pii: CD-18-0474. doi: 10.1158/2159-8290.CD-18- 0474.). The core is divided into three aims pertaining to 1) the development of infrastructure from HGSC tissue collection, 2) the use of PDX models to assess drug combinations in vivo, and 3) the use of HGSC organoids to assess drug combinations in vitro. The core will provide these studies, as well as relevant DNA repair and apoptosis biomarkers to the clinical trialists in the thee projects. The core will provide 1) ovarian cancer tissue collection infrastructure for participants in the SPORE, 2) the generation and analysis of short-term ovarian cancer organoid cultures, and 3) the generation and analysis of murine PDX models of ovarian cancer.

项目摘要 - 核心 3：类器官、模型系统和生物标志物核心该 Dana 的类器官、模型系统和生物标志物核心的总体目的是 Farber/哈佛大学癌症中心卵巢癌SPORE应用程序是为三者提供核心服务项目和其他核心项目将由 Alan D’Andrea、Joyce Liu 和 Neil Horowitz 博士指导。该核心的一个主要特征是我们在生成短期卵巢癌类器官方面的最新进展与来源肿瘤极为相似的培养物（Hill SJ、Decker B、Roberts EA、Horowitz NS、Muto MG、Worley MJ、Feltmate CM、Nucci MR、Swisher EM、Nguyen H、Yang C、Morizane R、 Kochupurakkal B、Do KT、Konstantinopoulos PA、Liu JF、Bonventre JV、Matulonis UA、Shapiro GI、Berkowitz RS、Crum CP、D’Andrea AD 短期患者来源的 DNA 修复抑制剂反应的预测。卵巢癌类器官。2018 年 9 月 13 日。pii：CD-18-0474 doi：10.1158/2159-8290.CD-18- 0474.) 核心分为三个目标，涉及 1) HGSC 组织的基础设施发展收集，2) 使用 PDX 模型评估体内药物组合，以及 3) 使用 HGSC 类器官核心将提供这些研究以及相关的DNA修复和体外评估药物组合。这些项目的核心将向临床试验者提供细胞凋亡生物标志物：1) 卵巢癌组织。 SPORE 参与者的收集基础设施，2) 短期卵巢的生成和分析癌症类器官培养，3) 卵巢癌小鼠 PDX 模型的生成和分析。